Membranoproliferative glomerulonephritis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
 
(7 intermediate revisions by 3 users not shown)
Line 2: Line 2:


{{Membranoproliferative glomerulonephritis}}
{{Membranoproliferative glomerulonephritis}}
{{CMG}} {{APM}} {{AE}} {{OO}}
{{CMG}} {{APM}} {{AE}} {{OO}} {{JSS}} {{SAH}}


== Overview ==
== Overview ==
The treatment of membranoproliferative glomerulonephritis depends on the cause of the disease.In infectious and haematological etiology treating the underlying infection will result in resolution of membranoproliferative glomerulonephritis.For autoimmune etiology immunosuppressive agents are given.The treatment also includes [[antihypertensive]] therapy, anticoagulation therapy and  anti-lipid therapy for nephrotic syndrome.
The optimal therapy for membranoproliferative glomerulonephritis depends on underlying etiology. In [[Infection|infectious]] and haematological etiology treating the underlying infection will result in resolution of membranoproliferative glomerulonephritis.For [[Autoimmunity|autoimmune]] etiology [[Immunosuppression|immunosuppressive]] agents are given.The treatment also includes [[antihypertensive]] therapy, [[Anticoagulant|anticoagulation therapy]] and  [[Statins|anti-lipid]] therapy for [[Nephrotic syndrome|nephrotic syndrome.]]


== Medical Therapy ==
== Medical Therapy ==
* Pharmacologic therapy is recommended for patients of membranoproliferative glomerulonephritis.
* Pharmacologic therapy is recommended for patients of membranoproliferative glomerulonephritis. Treatment options depends upon underlying etiology.<ref name="pmid29852477">{{cite journal| author=Bomback AS, Fervenza FC| title=Membranous Nephropathy: Approaches to Treatment. | journal=Am J Nephrol | year= 2018 | volume= 47 Suppl 1 | issue=  | pages= 30-42 | pmid=29852477 | doi=10.1159/000481635 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=29852477  }}</ref><ref name="pmid22859855">{{cite journal| author=Waldman M, Austin HA| title=Treatment of idiopathic membranous nephropathy. | journal=J Am Soc Nephrol | year= 2012 | volume= 23 | issue= 10 | pages= 1617-30 | pmid=22859855 | doi=10.1681/ASN.2012010058 | pmc=3458460 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22859855  }}</ref><ref name="pmid10495797">{{cite journal |vauthors=Wasserstein AG |title=Membranous glomerulonephritis |journal=J. Am. Soc. Nephrol. |volume=8 |issue=4 |pages=664–74 |date=April 1997 |pmid=10495797 |doi= |url=}}</ref><ref name="pmid15847250">{{cite journal |vauthors=Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L |title=The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis |journal=Clin. Nephrol. |volume=63 |issue=4 |pages=245–9 |date=April 2005 |pmid=15847250 |doi= |url=}}</ref>
* The treatment depends on the cause of the disease.
* Patients with autoimmune etiology are treated with [[immunosuppressive]] therapy.
* Patients with [[Autoimmune|autoimmuneetiology]]  are treated with [[immunosuppressive]] therapy
* Patients with infectious etiology are treated with antivirals or [[Antibiotic|antibiotics]] .
* Patients with infectious etiology are treated with antivirals or antibiotics depending on the cause.
* [[Hepatitis B]] and [[Hepatitis C]] are treated with antivirals.
* Hepatitis B and Hepatitis C are treated with antivirals.
** [[Leukemia|Leukemias]] and [[Lymphoma|lymphomas]] treated with [[chemotherapy]].
* Leukemias and lymphomas treated with chemotherapy.
* Other pharmacologic medical therapies for membranoproliferative glomerulonephritis include [[antihypertensive]] therapy, anticoagulation therapy and  anti-lipid therapy.
* Other pharmacologic medical therapies for membranoproliferative glomerulonephritis include [[antihypertensive]] therapy, anticoagulation therapy and  anti-lipid therapy.
'''1. Patients with autoimmune etiology'''
'''1. Patients with autoimmune etiology'''


'''1.1 Immunosuppressive therapy:'''
:*'''1.1 Immunosuppressive therapy:'''
:* Preferred regimen (1): [[Prednisone]] 0.5 mg/kg per day with [[cyclophosphamide]] IV for 3-5 months
:** Preferred regimen (1): [[Prednisone]] 0.5 mg/kg per day with [[cyclophosphamide]] IV for 3-5 months
:* Preferred regimen (2): [[Methylprednisolone]] 0.4 mg/kg per day given with [[cyclophosphamide]] 2.0 to 2.5 mg/kg per day given IV for 2, 4, and 6 months
:** Preferred regimen (2): [[Methylprednisolone]] 0.4 mg/kg per day given with [[cyclophosphamide]] 2.0 to 2.5 mg/kg per day given IV for 2, 4, and 6 months
:* Preferred regimen (3): [[Tacrolimus]] 0.05 mg/kg per day for PO for 12 months with a six-month taper
:** Preferred regimen (3): [[Tacrolimus]] 0.05 mg/kg per day for PO for 12 months with a six-month taper
:* Preferred regimen (4): [[Rituximab]] 3.5g/day IV for 6-12 months
:** Preferred regimen (4): [[Rituximab]] 3.5g/day IV for 6-12 months
'''2. Treatment for nephrotic sydnrome:'''
:*'''2. Treatment for nephrotic sydnrome:'''
 
:** '''2.1 Antihypertensive therapy'''
'''2.1 Antihypertensive therapy'''
:*** Preferred regimen (1) [[Angiotensin|Losartan]] PO for 50 mg q daily (100mg per day)
:* Preferred regimen (1) [[Angiotensin|Losartan]] PO for 50 mg q daily (100mg per day)
:** '''2.2 Anticoalgulation tharapy'''
'''2.2 Anticoalgulation tharapy'''
:*** [[Heparin|Low molecular weight or unfractionated heparin]], followed by PO [[warfarin]].
:* [[Heparin|Low molecular weight or unfractionated heparin]], followed by PO [[warfarin]].
:** '''2.3 Anti-lipid therapy'''
'''2.3 Anti-lipid therapy'''
:*** '''2.3.1 Life-style modification'''
 
:**** Decrease salt intake
'''2.3.1 Life-style modification'''
:**** Weight loss
:* Decrease salt intake
:*** '''2.3.2 Statins'''
:* Weight loss
:**** Preferred regimen (1): [[Atorvastatin clinical studies|Atorvastatin]] PO 10mg q daily
'''2.3.2 Statins'''
:* [[Atorvastatin clinical studies|Atorvastatin]] PO 10mg q daily
 
 
 
==References==
==References==
{{reflist|2}}
{{reflist|2}}

Latest revision as of 20:52, 2 August 2018


Membranoproliferative glomerulonephritis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Membranoproliferative glomerulonephritis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

Chest X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Membranoproliferative glomerulonephritis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Membranoproliferative glomerulonephritis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Membranoproliferative glomerulonephritis medical therapy

CDC on Membranoproliferative glomerulonephritis medical therapy

Membranoproliferative glomerulonephritis medical therapy in the news

Blogs on Membranoproliferative glomerulonephritis medical therapy

Directions to Hospitals Treating Membranoproliferative glomerulonephritis

Risk calculators and risk factors for Membranoproliferative glomerulonephritis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Ali Poyan Mehr, M.D. [2] Associate Editor(s)-in-Chief: Olufunmilola Olubukola M.D.[3] Jogeet Singh Sekhon, M.D. [4] Syed Ahsan Hussain, M.D.[5]

Overview

The optimal therapy for membranoproliferative glomerulonephritis depends on underlying etiology. In infectious and haematological etiology treating the underlying infection will result in resolution of membranoproliferative glomerulonephritis.For autoimmune etiology immunosuppressive agents are given.The treatment also includes antihypertensive therapy, anticoagulation therapy and anti-lipid therapy for nephrotic syndrome.

Medical Therapy

  • Pharmacologic therapy is recommended for patients of membranoproliferative glomerulonephritis. Treatment options depends upon underlying etiology.[1][2][3][4]
  • Patients with autoimmune etiology are treated with immunosuppressive therapy.
  • Patients with infectious etiology are treated with antivirals or antibiotics .
  • Hepatitis B and Hepatitis C are treated with antivirals.
  • Other pharmacologic medical therapies for membranoproliferative glomerulonephritis include antihypertensive therapy, anticoagulation therapy and anti-lipid therapy.

1. Patients with autoimmune etiology

  • 1.1 Immunosuppressive therapy:
  • 2. Treatment for nephrotic sydnrome:

References

  1. Bomback AS, Fervenza FC (2018). "Membranous Nephropathy: Approaches to Treatment". Am J Nephrol. 47 Suppl 1: 30–42. doi:10.1159/000481635. PMID 29852477.
  2. Waldman M, Austin HA (2012). "Treatment of idiopathic membranous nephropathy". J Am Soc Nephrol. 23 (10): 1617–30. doi:10.1681/ASN.2012010058. PMC 3458460. PMID 22859855.
  3. Wasserstein AG (April 1997). "Membranous glomerulonephritis". J. Am. Soc. Nephrol. 8 (4): 664–74. PMID 10495797.
  4. Ozsoy RC, Koopman MG, Kastelein JJ, Arisz L (April 2005). "The acute effect of atorvastatin on proteinuria in patients with chronic glomerulonephritis". Clin. Nephrol. 63 (4): 245–9. PMID 15847250.

Template:WH Template:WS